METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
DASH diet tested as a treatment for Kids' fatty liver
Disease control Not yet recruitingThis study looks at whether the DASH diet (a heart-healthy eating plan) can improve liver health in children aged 11-18 with a fatty liver condition called MASLD. About 88 children will either follow the DASH diet or continue their usual eating habits for 12 weeks. Researchers wi…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Antalya Training and Research Hospital • Aim: Disease control
Last updated May 17, 2026 07:06 UTC
-
New drug combo targets genetic fatty liver disease
Disease control Not yet recruitingThis study tests a new drug, ALN-PNP, alone or with a diabetes/weight-loss drug (like tirzepatide), in adults with a genetic form of fatty liver disease (MASLD). The goal is to see if lowering a specific protein (PNPLA3) can reduce liver fat. About 204 people with a specific gene…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Common supplement SAMe tested to block liver cancer in fatty liver patients
Prevention Not yet recruitingThis study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo daily for 12 months. Researchers will measure changes in a blood test t…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Prevention
Last updated May 07, 2026 18:42 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Not yet recruitingThis early-stage study tests the safety and how the body processes the drug miricorilant in 15 adults with MASH, a serious fatty liver condition. Participants will take the drug and be monitored for side effects and drug levels in the blood. The goal is to gather information for …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 07:05 UTC